44
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties Contribute to Tumor Generation, Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cells with sphere forming capacity, spheroid cells, are present in the malignant ascites of patients with epithelial ovarian cancer (EOC) and represent a significant impediment to efficacious treatment due to their putative role in progression, metastasis and chemotherapy resistance. The exact mechanisms that underlie EOC metastasis and drug resistance are not clear. Understanding the biology of sphere forming cells may contribute to the identification of novel therapeutic opportunities for metastatic EOC. Here we generated spheroid cells from human ovarian cancer cell lines and primary ovarian cancer. Xenoengraftment of as few as 2000 dissociated spheroid cells into immune-deficient mice allowed full recapitulation of the original tumor, whereas >10 5 parent tumor cells remained non-tumorigenic. The spheroid cells were found to be enriched for cells with cancer stem cell-like characteristics such as upregulation of stem cell genes, self-renewal, high proliferative and differentiation potential, and high aldehyde dehydrogenase (ALDH) activity. Furthermore, spheroid cells were more aggressive in growth, migration, invasion, scratch recovery, clonogenic survival, anchorage-independent growth, and more resistant to chemotherapy in vitro. 13C-glucose metabolic studies revealed that spheroid cells route glucose predominantly to anaerobic glycolysis and pentose cycle to the detriment of re-routing glucose for anabolic purposes. These metabolic properties of sphere forming cells appear to confer increased resistance to apoptosis and contribute to more aggressive tumor growth. Collectively, we demonstrated that spheroid cells with cancer stem cell-like characteristics contributed to tumor generation, progression and chemotherapy resistance. This study provides insight into the relationship between tumor dissemination and metabolic attributes of human cancer stem cells and has clinical implications for cancer therapy.

          Related collections

          Most cited references37

          • Record: found
          • Abstract: not found
          • Article: not found

          On the origin of cancer cells.

          O WARBURG (1956)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Identification of pancreatic cancer stem cells.

            Emerging evidence has suggested that the capability of a tumor to grow and propagate is dependent on a small subset of cells within a tumor, termed cancer stem cells. Although data have been provided to support this theory in human blood, brain, and breast cancers, the identity of pancreatic cancer stem cells has not been determined. Using a xenograft model in which primary human pancreatic adenocarcinomas were grown in immunocompromised mice, we identified a highly tumorigenic subpopulation of pancreatic cancer cells expressing the cell surface markers CD44, CD24, and epithelial-specific antigen (ESA). Pancreatic cancer cells with the CD44(+)CD24(+)ESA(+) phenotype (0.2-0.8% of pancreatic cancer cells) had a 100-fold increased tumorigenic potential compared with nontumorigenic cancer cells, with 50% of animals injected with as few as 100 CD44(+)CD24(+)ESA(+) cells forming tumors that were histologically indistinguishable from the human tumors from which they originated. The enhanced ability of CD44(+)CD24(+)ESA(+) pancreatic cancer cells to form tumors was confirmed in an orthotopic pancreatic tail injection model. The CD44(+)CD24(+)ESA(+) pancreatic cancer cells showed the stem cell properties of self-renewal, the ability to produce differentiated progeny, and increased expression of the developmental signaling molecule sonic hedgehog. Identification of pancreatic cancer stem cells and further elucidation of the signaling pathways that regulate their growth and survival may provide novel therapeutic approaches to treat pancreatic cancer, which is notoriously resistant to standard chemotherapy and radiation.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Hypoxia-inducible factors, stem cells, and cancer.

              Regions of severe oxygen deprivation (hypoxia) arise in tumors due to rapid cell division and aberrant blood vessel formation. The hypoxia-inducible factors (HIFs) mediate transcriptional responses to localized hypoxia in normal tissues and in cancers and can promote tumor progression by altering cellular metabolism and stimulating angiogenesis. Recently, HIFs have been shown to activate specific signaling pathways such as Notch and the expression of transcription factors such as Oct4 that control stem cell self renewal and multipotency. As many cancers are thought to develop from a small number of transformed, self-renewing, and multipotent "cancer stem cells," these results suggest new roles for HIFs in tumor progression.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS One
                PLoS ONE
                plos
                plosone
                PLoS ONE
                Public Library of Science (San Francisco, USA )
                1932-6203
                2014
                7 January 2014
                : 9
                : 1
                : e84941
                Affiliations
                [1 ]Departments of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York, United States of America
                [2 ]Immunology; Roswell Park Cancer Institute, Buffalo, New York, United States of America
                [3 ]Center for Immunotherapy; Roswell Park Cancer Institute, Buffalo, New York, United States of America
                [4 ]Surgical Oncology, Roswell Park Cancer Institute, Buffalo, New York, United States of America
                [5 ]Urology Oncology, Roswell Park Cancer Institute, Buffalo, New York, United States of America
                [6 ]Pharmacology & Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, United States of America
                [7 ]Pathology, Roswell Park Cancer Institute, Buffalo, New York, United States of America
                [8 ]Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, United States of America
                [9 ]Atlantic Health System Morristown/Overlook Medical Centers, Women’s Cancer Center, Morristown and Summit, New Jersey, United States of America
                Cedars-Sinai Medical Center, United States of America
                Author notes

                Competing Interests: The authors have declared that no competing interests exist.

                Conceived and designed the experiments: JL FQ NT XW WJH SBL KO. Performed the experiments: JL NT AB ZQ. Analyzed the data: JL FQ NT AB ZQ PMF KO. Contributed reagents/materials/analysis tools: CDM. Wrote the paper: JL FQ KO. These authors contributed equally to the study: JL FQ.

                Article
                PONE-D-13-37360
                10.1371/journal.pone.0084941
                3883678
                24409314
                1070b903-0d54-4b6b-ba59-db8dd8fa89ce
                Copyright @ 2014

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 10 September 2013
                : 29 November 2013
                Page count
                Pages: 13
                Funding
                This work was supported in part by Cancer Research Institute Ovarian Cancer Working Group Grant, Cancer Vaccine Collaborative Grant of the Cancer Research Institute and Ludwig Institute for Cancer Research, Anna-Maria Kellen Clinical Investigator Award of the Cancer Research Institute (to KO), Roswell Park Cancer Institute Alliance Foundation, NIH P30 CA016056; NIH R01CA158318-01A1 and RPCI-UPCI Ovarian Cancer SPORE P50CA159981-01A1. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article
                Biology
                Molecular Cell Biology
                Cellular Types
                Stem Cells
                Stem Cell Lines
                Medicine
                Obstetrics and Gynecology
                Gynecologic Cancers
                Oncology
                Basic Cancer Research
                Metastasis
                Tumor Physiology
                Cancer Treatment
                Chemotherapy and Drug Treatment
                Cancers and Neoplasms
                Gynecological Tumors
                Ovarian Cancer

                Uncategorized
                Uncategorized

                Comments

                Comment on this article